PL3137097T3 - Leczenie i profilaktyka choroby Alzheimera (AD) - Google Patents
Leczenie i profilaktyka choroby Alzheimera (AD)Info
- Publication number
- PL3137097T3 PL3137097T3 PL15720058.5T PL15720058T PL3137097T3 PL 3137097 T3 PL3137097 T3 PL 3137097T3 PL 15720058 T PL15720058 T PL 15720058T PL 3137097 T3 PL3137097 T3 PL 3137097T3
- Authority
- PL
- Poland
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985710P | 2014-04-29 | 2014-04-29 | |
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059337 WO2015165964A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3137097T3 true PL3137097T3 (pl) | 2023-09-11 |
Family
ID=50555097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15720058.5T PL3137097T3 (pl) | 2014-04-29 | 2015-04-29 | Leczenie i profilaktyka choroby Alzheimera (AD) |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10646565B2 (pl) |
| EP (1) | EP3137097B1 (pl) |
| JP (1) | JP2017514831A (pl) |
| KR (1) | KR102460465B1 (pl) |
| CN (1) | CN106535924A (pl) |
| AU (3) | AU2015254661A1 (pl) |
| CA (1) | CA2946929A1 (pl) |
| ES (1) | ES2953381T3 (pl) |
| PL (1) | PL3137097T3 (pl) |
| WO (2) | WO2015165964A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3137094T3 (da) * | 2014-04-29 | 2023-02-27 | Advantage Therapeutics Inc | Behandling og forebyggelse af alzheimers sygdom (ad) |
| KR102388363B1 (ko) * | 2014-04-29 | 2022-04-19 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| JP2017514831A (ja) | 2014-04-29 | 2017-06-08 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | アルツハイマー病（ａｄ）の処置および予防 |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| AT413946B (de) * | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| WO2009105641A2 (en) * | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| JP6088422B2 (ja) * | 2010-03-29 | 2017-03-01 | ノバルティス アーゲー | ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物 |
| EP2659908A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| KR102388363B1 (ko) | 2014-04-29 | 2022-04-19 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| DK3137094T3 (da) * | 2014-04-29 | 2023-02-27 | Advantage Therapeutics Inc | Behandling og forebyggelse af alzheimers sygdom (ad) |
| JP2017514831A (ja) | 2014-04-29 | 2017-06-08 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | アルツハイマー病（ａｄ）の処置および予防 |
-
2015
- 2015-04-29 JP JP2016565238A patent/JP2017514831A/ja active Pending
- 2015-04-29 WO PCT/EP2015/059337 patent/WO2015165964A1/en not_active Ceased
- 2015-04-29 PL PL15720058.5T patent/PL3137097T3/pl unknown
- 2015-04-29 CA CA2946929A patent/CA2946929A1/en not_active Abandoned
- 2015-04-29 US US15/307,714 patent/US10646565B2/en active Active
- 2015-04-29 AU AU2015254661A patent/AU2015254661A1/en not_active Abandoned
- 2015-04-29 CN CN201580029876.1A patent/CN106535924A/zh active Pending
- 2015-04-29 WO PCT/EP2015/059355 patent/WO2015165974A1/en not_active Ceased
- 2015-04-29 ES ES15720058T patent/ES2953381T3/es active Active
- 2015-04-29 EP EP15720058.5A patent/EP3137097B1/en active Active
- 2015-04-29 KR KR1020167033323A patent/KR102460465B1/ko active Active
-
2020
- 2020-03-17 US US16/821,557 patent/US11147873B2/en active Active
-
2021
- 2021-01-08 AU AU2021200093A patent/AU2021200093B2/en active Active
- 2021-09-23 US US17/482,579 patent/US20220062412A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201099A patent/AU2024201099B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015165964A8 (en) | 2017-02-09 |
| EP3137097B1 (en) | 2023-06-21 |
| EP3137097A1 (en) | 2017-03-08 |
| US20170056495A1 (en) | 2017-03-02 |
| KR20160145820A (ko) | 2016-12-20 |
| US11147873B2 (en) | 2021-10-19 |
| WO2015165974A1 (en) | 2015-11-05 |
| ES2953381T3 (es) | 2023-11-13 |
| WO2015165964A1 (en) | 2015-11-05 |
| AU2024201099B2 (en) | 2026-07-02 |
| AU2024201099A1 (en) | 2024-03-14 |
| JP2017514831A (ja) | 2017-06-08 |
| AU2021200093A1 (en) | 2021-03-18 |
| AU2015254661A9 (en) | 2019-08-01 |
| AU2015254661A1 (en) | 2016-11-10 |
| CN106535924A (zh) | 2017-03-22 |
| CA2946929A1 (en) | 2015-11-05 |
| US10646565B2 (en) | 2020-05-12 |
| AU2021200093B2 (en) | 2024-03-07 |
| US20220062412A1 (en) | 2022-03-03 |
| EP3137097C0 (en) | 2023-06-21 |
| US20200338192A1 (en) | 2020-10-29 |
| KR102460465B1 (ko) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247085A0 (en) | Methods for treating Alzheimer's disease | |
| IL276315A (en) | Donepezil preparations and a method for treating Alzheimer's disease | |
| ZA201605341B (en) | Methods of treating alzheimer's disease | |
| IL266047A (en) | Methods and preparations for the treatment of Fabry disease | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| IL248592A0 (en) | Treatment of Crohn's disease using delayed-release 6-mercaptofurin | |
| PT3458045T (pt) | Ebselen para uso no tratamento da doença de ménière | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL248935A0 (en) | Diagnostic testing and treatment/prevention of Alzheimer's disease | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| EP3137097C0 (en) | TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE | |
| IL251135A (en) | A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| PT3137093T (pt) | Tratamento e prevenção da doença de alzheimer (da) | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201622116D0 (en) | Treatment of liver disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease | |
| AU2015904411A0 (en) | Compositions and methods for the treatment of Alzheimer's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| GB201610906D0 (en) | Treatment of cardiovascular disease | |
| GB201504413D0 (en) | Treatment of disease | |
| HK1230506A1 (en) | Treatment of crohn's disease with delayed-release 6-mercaptopurine |